All the Embryo's a Stage, and Olig2 in Its Time Plays Many Parts  by Gaber, Zachary B. & Novitch, Bennett G.
Neuron
PreviewsAll the Embryo’s a Stage, and Olig2
in Its Time Plays Many PartsZachary B. Gaber1,2,3 and Bennett G. Novitch1,2,3,*
1Department of Neurobiology
2Edythe and Eli Broad Center for Regenerative Medicine and Stem Cell Research
3Molecular Biology Institute
David Geffen School of Medicine at UCLA, 610 Charles E. Young Dr. East, Los Angeles, CA 90095, USA
*Correspondence: bnovitch@ucla.edu
DOI 10.1016/j.neuron.2011.02.037
Olig2 is essential for the selection of motor neuron and oligodendrocyte fates and the choice of neural
progenitors to either proliferate or differentiate. Three new studies demonstrate that these diverse actions
of Olig2 are gated by phosphorylation at two distinct motifs and that Olig2’s proliferative function acts in
opposition to the p53 tumor suppressor pathway.The exquisite cellular diversity and archi-
tecture of the central nervous system
arises from the actions of a small number
of regulatory molecules that are reused at
different times to achieve radically dispa-
rate ends. A notable example of this
phenomenon is the basic-helix-loop-helix
(bHLH) transcription factor Olig2, which
plays a central role in directing cell fate
choices and controlling cell proliferation.
In the early embryo, Olig2 first establishes
a ventral domain of motor neuron progen-
itors and then promotes their cell cycle
exit and neuronal differentiation (Mizugu-
chi et al., 2001; Novitch et al., 2001). Later
in development, Olig2 directs the forma-
tion of oligodendrocyte precursors and
mature oligodendrocytes (Lu et al., 2002;
Park et al., 2002; Takebayashi et al.,
2002; Zhou and Anderson, 2002; Zhou
et al., 2001). Within the adult forebrain,
Olig2 is expressed by a subset of Type
C transit amplifying progenitors in the
subventricular zone as well as cycling
NG2+ oligodendrocyte precursors (Jack-
son et al., 2006; Menn et al., 2006). Olig2
is further associated with pathological
proliferation in all grades of glioma, and
its presence strongly correlates with
tumor forming potential (Ligon et al.,
2007).
Olig2 thus acts as a multifaceted tran-
scription factor: promoting both neuronal
and glial fates and directing the differenti-
ation or proliferation of progenitors at
different places and times. The basis of
these diverse activities, however, has
remained mysterious. In this issue of
Neuron, two studies by Li et al. (2011)and Sun et al. (2011) demonstrate that
Olig2’s activities in both cell fate specifi-
cation and cell proliferation are guided
by specific phosphorylation events. A
companion study by Mehta et al. (2011)
published in Cancer Cell further reveals
that Olig2’s ability to stimulate neural
stem cell proliferation ismediated through
its ability to oppose the p53 tumor sup-
pressor pathway. Together, these studies
cast a new spotlight on the way in which
posttranslational modifications enable
one protein to coordinate multiple func-
tions in the developing nervous system.
Basic-helix-loop-helix (bHLH) tran-
scription factors typically bind DNA as
either homodimers or heterodimers with
related proteins through their HLH dimer-
ization domains. Li et al. (2011) demon-
strate that the phosphorylation of Olig2
on Serine-147 (S147), a highly conserved
residue within its HLH domain, strongly
influences its dimerization preferences
and thereby guides its activity in motor
neuron and oligodendrocyte fate specifi-
cation. Substitution of S147 with alanine
(S147A) results in an Olig2 protein that is
incapable of inducing motor neuron
formation but still competent for oligoden-
drocyte precursor induction, both in vivo
and in cultured cells. Interestingly, the
Olig2 S147A mutant protein displays a
reduced ability to form homodimers and
instead shows a higher affinity for other
bHLH proteins such as the proneural
bHLH protein Ngn2. Thus, S147 phos-
phorylation appears to gate the composi-
tion of the Olig2 DNA binding complex,
permitting Olig2 to form a motor neuron-Neuron 6producing homodimeric complex while
removal of this phosphate favors the
formation of heterodimeric complexes
associated with oligodendrocyte forma-
tion (Figure 1).
These striking findings raise a number
of questions. First, what is the endoge-
nous composition of the Olig2 hetero-
dimers associated with oligodendrocyte
formation? Olig2 has been previously
shown to be capable of associating with
the bHLH proteins Ngn2 and E47 (Lee
et al., 2005) and Li et al. (2011) indeed
provide some evidence that Olig2 S147A
has an increased affinity for Ngn2. How-
ever, since oligodendrocyte precursors
do not normally express Ngn2, other
dimerization partners may be more rele-
vant in these cells. Second, how does
Olig2’s ability to form homodimers versus
heterodimers explain its differential activ-
ities? It seems likely that the choice of
binding partners could recruit Olig2 to
distinct genomic sites important for either
motor neuron or oligodendrocyte forma-
tion. Alternatively, Olig2 homodimer and
heterodimer complexes could converge
upon a common set of genes, but the
nature of the complex could instead influ-
ence whether those genes are activated
or repressed. These issues should be
addressable through future investigations
into the genomic targets of the Olig2 com-
plexes in the context of both motor
neuron and oligodendrocyte formation.
Lastly, which kinases and phosphatases
regulate S147 phosphorylation, and how
are they controlled? Li et al. (2011) sug-
gest that protein kinase A may be a9, March 10, 2011 ª2011 Elsevier Inc. 833
Figure 1. Olig2 Activity in Neural Development Is Regulated by TwoDistinct Phosphorylation
Events
(A) Early in development, Olig2 is phosphorylated at S147, and this modification directs the formation of
Olig2 homodimers that promote the expression of motor neuron-specific genes and silence others.
(B) The transition to oligodendrocyte progenitor specification is facilitated by the dephosphorylation of
S147, enabling Olig2 to form heterodimers with bHLH proteins such as Ngn2, E47, and others that induce
the expression of oligodendrocyte progenitor-specific genes and suppress neuronal development.
(C) Within adult neural progenitors, the phosphorylation of a triple-serinemotif (S10, S13, S14) near Olig2’s
N terminus (NTD) is necessary for Olig2 enhancement of proliferation. Triple-phosphorylated Olig2
reduces p53 acetylation and thereby limits p53’s ability to activate its cell cycle arrest and apoptotic
effectors.
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Previewsrelevant candidate, but direct testing of its
function in this process is needed to
confirm its role.
Later in development, Olig2 becomes
essential for the proliferation of neural
progenitors (Ligon et al., 2007). Sun
et al. (2011) report here that this activity
requires the phosphorylation of Olig2 at
a distinct triple-serine motif (S10, S13,
and S14) near its amino-terminus (Fig-
ure 1). The growth of Olig2 mutant pro-
genitors can accordingly be rescued and
in some cases enhanced by the introduc-
tion of a triple phosphomimetic form of
Olig2, but not by a triple phosphomutant
form. Significantly, all forms of Olig2
investigated were able to restore oligo-
dendrocyte formation, indicating that
phosphorylation at the triple-serine motif
selectively regulates the ability of Olig2
to promote neural progenitor proliferation
and is dispensable for its fate-specifying
functions. Given the distance of this motif
from the HLH domain, it seems likely
that this phosphorylation affects Olig2
activity independent of the dimerization
preferences associated with S147
phosphorylation.
The molecular interactions that require
the phosphorylation of Olig2’s triple-
serine motif are examined further in the
companion study by Mehta et al. (2011).
Olig2 has previously been shown to
directly repress the p53 tumor-sup-
pressor pathway effector p21WAF1/CIP1834 Neuron 69, March 10, 2011 ª2011 Elsev(Ligon et al., 2007). Mehta et al. (2011)
now provide evidence that Olig2 has
a much broader effect on the entire p53
pathway. In normal cells, DNA damage
stimulates the activity of both p53 and
p21 to reduce proliferation and induce
apoptosis (Figure 1). Mehta et al. (2011)
demonstrate that Olig2 mutant cells are
more prone to cell cycle arrest following
DNA damage and that this sensitivity
can be overcome by removing p53 func-
tion. Thus, Olig2 and p53 appear to act
in opposition to each other in modulating
proliferation following genotoxic damage.
Olig2 is further shown to suppress p53
acetylation, a posttranslational modifica-
tion that is associated with its transcrip-
tional activity, and impedes p53 binding
to several known enhancer sites. The
mechanism by which Olig2 carries out
these functions remains unclear, though
it strikingly requires the newly discovered
triple-serine motif.
Both studies show that Olig2 expres-
sion is necessary for optimal proliferation
of glioma cells and essential for their
ability to form tumors when transplanted
into SCIDmice. Mehta et al. (2011) extend
this observation by uncovering that Olig2
becomes dispensable for tumor formation
in the absence of p53. Furthermore, Sun
et al. (2011) have found that the triple-
serine motif is highly phosphorylated in
several glioma lines and that the phos-
phomimetic Olig2 protein is even moreier Inc.tumorigenic than the wild-type protein.
These findings together strongly support
the authors’ contention that the ability of
Olig2 to promote neural stem and progen-
itor cell proliferation is mediated through
its opposition to the p53 pathway and
that this mechanism contributes to the
pathology of many human gliomas.
While the Sun and Mehta studies
provide important new insights into the
role of Olig2 in tumor formation, many
questions remain unresolved. First, how
does the phosphorylation of the triple-
serine motif alter Olig2 interactions with
regulators of p53 and other pathways?
Second, how prevalent is the Olig2-medi-
ated suppression of p53 within human
gliomas? Although Sun et al. (2011) report
that Olig2 was phosphorylated in several
glioma samples, a more systematic
survey is needed to determine the gener-
ality of this proposed mechanism for
glioma pathogenesis and assess its impli-
cations for human disease. Third, what
are the kinases and phosphatases that
act upon the triple-serine motif, and how
are they regulated? Finally, could the
S147 and triple-serine phosphorylation
events be combined to further expand
the diversity of Olig2’s function in the
nervous system?
In summary, these papers provide an
elegant example of how developmentally
regulated phosphorylation events endow
Olig2 with its unique biological functions.
The findings further suggest a general
strategy through which posttranslational
modifications can enable single transcrip-
tion factors to be co-opted for different
purposes. Moreover, the correlation of
Olig2 phosphorylation at the triple-serine
motif with human gliomas make the
removal of this modification a very prom-
ising avenue for the development of new
therapies to combat glial tumor growth.
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Though transmitters can be released from astrocytes, the conditions that permit their modulation of synaptic
transmission are under debate. Santello et al. in this issue of Neuron now show that TNFa promotes a burst
mode of glial transmitter release that escapes reuptake processes allowing access to neuronal NMDA
receptors.Seventeen years ago a quiet revolution in
neuroscience began with the discovery
that astrocytes, the major subtype of
glia, could excite and activate neighboring
neurons (Nedergaard, 1994; Parpura
et al., 1994). One of these studies demon-
strated the importance of the astrocytic
release of the chemical transmitter gluta-
mate (Parpura et al., 1994) in a process
that has been termed gliotransmission.
This observation, initially demonstrated
in culture, moved to brain slice studies
and more recently in vivo. In this issue of
Neuron, Andrea Volterra and colleagues
(Santello et al., 2011) now show that the
presence of proinflammatory cytokine
TNFa acts as a state-dependent switch
to control the functional nature of
gliotransmission.
Synapses are increasingly recognized
to be tripartite structures, pre- and post-
synaptic neurons and surrounding
astrocytes (Figure 1), in which astrocytes
actively modulate synaptic activity as
well as support neuronal function (Araque
et al., 1999). Astrocytes respond tosynaptic activity with Ca2+ elevations,
which leads to the release of gliotransmit-
ters, such as glutamate. This astrocytic
Ca2+ increase has the potential to
contribute to synaptic activity by the
activation of NMDA receptors or metabo-
tropic glutamate receptors (Haydon and
Carmignoto, 2006). With the identification
of additional gliotransmitters and more
evidence supporting this process in brain
function have come recent papers with
observations that challenge the relevance
of gliotransmission, leading to what has
been termed ‘‘the great glial debate’’
(Smith, 2010). Now, Santello et al. (2011)
report a new observation concerning
a state-dependence of gliotransmission
that provides insights into the regulation
of transmitter release from glia. They
show that Ca2+-dependent glutamate-
mediated gliotransmission requires the
presence of the proinflammatory cytokine
TNFa. Interestingly, TNFa levels aremodu-
lated by sleep-wake cycles (Krueger,
2008), suggesting that astrocytes might
modulate synapses in a diurnal manner.In 2007, Volterra’s group demonstrated
that astrocytes modulate excitatory
synapses of granule cells of the dentate
gyrus through the Ca2+ dependent
release of glial-derived glutamate (Jour-
dain et al., 2007). In that study, they
demonstrated that the activation of P2Y1
receptors, which are enriched in astro-
cytes, caused an NMDA receptor depen-
dent increase in the frequency ofmEPSCs
that was attenuated if Ca2+ elevations in
astrocytes were inhibited. Amid the series
of recent conflicting observations in the
study of gliotransmission, it was shown
that TNFa could potently augment the
release of glutamate from astrocytes
(Domercq et al., 2006), which prompted
the authors to ask whether TNFa was
required for the form of gliotransmission
that they were studying.
Santello et al. (2011) first confirm that
the P2Y1 receptor agonist 2MeSADP
elevates mEPSC frequency and that
astrocytic dialysis of the Ca2+ buffer
BAPTA prevents this form of synaptic
modulation. Having demonstrated that9, March 10, 2011 ª2011 Elsevier Inc. 835
